SK Capital Partners Take Majority of IBA Molecular

New York-based SK Capital Partners is spinning out a new company - IBA Molecular Imaging – from the radiopharmaceutical division of Ion Beam Applications S.A., the firm announced. IBA Molecular is a manufacturer and distributor of radioactive isotopes used for medical imaging, with more than 50 locations across the world. The transaction is valued at approximately €180 million ($234 million). SK Capital will own 60% of the recapitalized entity, and IBA will retain a 40% stake, the firm said.

DealsNorth AmericaUSBriefs